Obstetric and Gynecologic Imaging

What Is the Best Imaging for Routine Nuchal Translucency Screening at 11-14 Weeks?

·
What Is the Best Imaging for Routine Nuchal Translucency Screening at 11-14 Weeks?

A 29-year-old primigravida patient presents for her first-trimester appointment at 12 weeks and 4 days of gestation. She has elected to proceed with combined first-trimester screening for aneuploidy, which requires a precise ultrasound measurement of the fetal nuchal translucency (NT). As the ordering clinician, you need to select the most appropriate initial imaging study to obtain this measurement, confirm gestational age, and perform a basic anatomic survey. This article provides a detailed clinical workflow for this routine screening scenario, grounded in the American College of Radiology (ACR) Appropriateness Criteria. For this initial evaluation, the ACR rates a transabdominal ultrasound of the pregnant uterus as Usually appropriate.

Who Fits This Clinical Scenario for Routine Nuchal Translucency Measurement?

This guidance applies specifically to pregnant patients undergoing an initial imaging evaluation as part of routine first-trimester screening. The inclusion criteria are precise and critical for the test’s validity:

  • Gestational Age: The patient must be between 11 weeks 0 days and 13 weeks 6 days of gestation. This corresponds to a fetal crown-rump length (CRL) of 45 mm to 84 mm. The normative data for NT measurements are strictly validated for this developmental window.
  • Number of Fetuses: This workflow is appropriate for both singleton and twin gestations.
  • Clinical Indication: The scan is being performed for routine screening in a patient who has not had a prior NT measurement during the current pregnancy.

It is crucial to distinguish this scenario from similar but distinct clinical presentations. This workflow does not apply to patients who have already undergone an ultrasound where the nuchal translucency was found to be increased. An abnormal or enlarged NT measurement is a specific finding that triggers a different diagnostic cascade, detailed in separate ACR guidelines for increased NT in singletons, dichorionic twins, or monochorionic twins. Applying this routine screening workflow to a patient with a known abnormality would be inappropriate.

What Are You Screening For with a Routine Nuchal Translucency Measurement?

The nuchal translucency scan is a screening test, not a diagnostic one. Its primary purpose is to identify fetuses at an increased risk for certain conditions, warranting further discussion and potential diagnostic testing. The measurement of the subcutaneous fluid collection at the back of the fetal neck is a powerful but nonspecific marker.

Aneuploidy (Chromosomal Abnormalities): This is the most well-known application of NT screening. An increased NT measurement is associated with a higher risk for conditions like Trisomy 21 (Down syndrome), Trisomy 18 (Edwards syndrome), and Trisomy 13 (Patau syndrome). The NT value is a key input, along with maternal age and maternal serum analytes (free β-hCG and PAPP-A), into a combined algorithm that calculates a patient-specific risk score.

Congenital Heart Defects: A significantly increased NT is one of the strongest early markers for major congenital heart disease, even in fetuses with normal chromosomes. The underlying pathophysiology is thought to involve altered fetal hemodynamics or lymphatic development in the setting of a cardiac anomaly. An enlarged NT may prompt a recommendation for a detailed fetal echocardiogram later in pregnancy.

Other Genetic Syndromes and Structural Anomalies: Beyond common aneuploidies and cardiac defects, an increased NT can be an early sign of a wide array of other conditions. These include skeletal dysplasias, diaphragmatic hernia, and single-gene disorders such as Noonan syndrome. It serves as a general indicator that fetal development may be atypical, prompting a more thorough evaluation.

It is essential to counsel patients that the vast majority of fetuses will have a normal NT measurement. Furthermore, even among those with a measurement at the upper limits of normal, most will ultimately be healthy and have no underlying condition. The goal of the screen is to stratify risk and identify the small subset of pregnancies that benefit from more intensive surveillance and diagnostic options.

Why Is Transabdominal Ultrasound the Recommended First Step for Routine NT Measurement?

The ACR designates `US pregnant uterus transabdominal` as Usually appropriate for the initial evaluation of nuchal translucency in a routine screening setting. This recommendation is based on its excellent balance of diagnostic capability, safety, and accessibility.

The transabdominal approach is non-invasive and uses no ionizing radiation (adult and pediatric radiation relative level: O). At 11 to 14 weeks gestation, it typically provides sufficient resolution to perform the highly standardized measurements required for NT evaluation. A certified sonographer can obtain the necessary midsagittal view of the fetus to measure the CRL for accurate dating and the maximal NT thickness. This approach also allows for a crucial, albeit limited, early anatomic survey, including confirmation of fetal viability, assessment of the cranium, stomach, bladder, limbs, and the presence of the nasal bone—another important marker in aneuploidy screening.

Rationale for Alternative Study Ratings

  • `US pregnant uterus transvaginal` is rated May be appropriate. While transvaginal ultrasound offers superior image resolution due to the higher frequency transducer’s proximity to the uterus, it is more invasive and not required for the majority of patients. It serves as an essential problem-solving tool. If the transabdominal approach fails to yield adequate images due to factors like maternal body habitus, a retroverted uterus, or a persistently unfavorable fetal position, a transvaginal scan is the appropriate next step to obtain the necessary measurements.
  • `US duplex Doppler pregnant uterus` is rated Usually not appropriate. Duplex Doppler is a functional imaging technique used to assess blood flow. It plays no role in the anatomic measurement of the nuchal translucency. Furthermore, professional society guidelines recommend cautious and limited use of Doppler ultrasound in the first trimester, adhering to the As Low As Reasonably Achievable (ALARA) principle to minimize fetal energy exposure.
  • `US echocardiography fetal` is also rated Usually not appropriate for this initial screening. A formal fetal echocardiogram is a highly specialized and detailed examination of the fetal heart, typically performed between 18 and 22 weeks. While an increased NT measurement from this initial scan may be a primary indication for a future fetal echo, it is not the correct test to order for the screening itself.

For optimal results, the imaging request should clearly state “First-trimester screen with nuchal translucency measurement” to ensure the performing site allocates a sonographer certified in this specific technique.

What Is the Downstream Workflow After a Routine Nuchal Translucency Scan?

The result of the NT scan is not interpreted in isolation. It is a component of a multi-marker screening test, and the subsequent workflow depends on the final, integrated risk assessment.

  • If the NT is Normal and Combined Screen is Low-Risk: The patient is considered to be at low risk for the screened conditions. They can be reassured and should continue with routine prenatal care. The next standard imaging milestone is the comprehensive fetal anatomic survey, typically performed between 18 and 22 weeks of gestation.
  • If the NT is Increased or the Combined Screen is High-Risk: This result does not diagnose a problem; it indicates that the pregnancy is at a higher statistical risk. This finding should prompt a referral for genetic counseling. The counselor will discuss the results in detail and present the options for definitive diagnostic testing, which include chorionic villus sampling (CVS) in the first trimester or amniocentesis in the second trimester. The patient should also be counseled about the option of cell-free DNA (cfDNA) screening, which is a highly sensitive secondary screening test.
  • If the NT is Significantly Increased with a Normal Karyotype: Even if diagnostic testing reveals normal chromosomes, a significantly enlarged NT (e.g., ≥3.5 mm) remains a concern. This finding warrants a detailed second-trimester anatomic survey and a formal fetal echocardiogram to evaluate for structural anomalies, particularly cardiac defects, that are not associated with aneuploidy.

Pitfalls to Avoid (and When to Get Help)

Several common pitfalls can compromise the value of first-trimester NT screening.

  • Incorrect Timing: Performing the scan outside the 11-week to 14-week (CRL 45-84 mm) window invalidates the measurement, as the normative data no longer apply.
  • Using a Non-Certified Sonographer: NT measurement requires rigorous training and adherence to strict technical criteria (e.g., proper magnification, midsagittal plane, neutral fetal position). Measurements from uncertified providers should not be used for risk calculation.
  • Misinterpreting the Result as Diagnostic: It is critical to communicate to patients that this is a screening test that quantifies risk, not a diagnostic test that provides a definitive answer.
  • Ignoring an Increased NT with a “Normal” cfDNA Screen: While cfDNA is an excellent screen for common aneuploidies, a very large NT can indicate other genetic syndromes or major structural defects not detected by cfDNA. Such cases still warrant a detailed anatomic survey and fetal echocardiogram.

If the transabdominal scan is technically limited and a clear measurement cannot be obtained, the appropriate escalation is to proceed with a transvaginal ultrasound during the same session or to have the patient return when fetal positioning may be more favorable.

Related ACR Topics and Tools

This article covers one specific scenario within the broader topic of first-trimester screening. For a comprehensive overview of all related clinical variants, including the workup of an already-identified increased nuchal translucency, please consult the parent topic guide.

For additional decision support and technical details, the following GigHz resources are available:

Frequently Asked Questions

Why is the 11 to 14-week window so strict for nuchal translucency measurement?

The normative data used to calculate risk are based on thousands of measurements correlated with fetal crown-rump length (CRL) specifically within this window (45-84 mm). Before 11 weeks, the fetus is too small for reliable measurement. After 14 weeks, the lymphatic system typically develops further and may drain the fluid, or an increased NT may evolve into nuchal edema or cystic hygroma, which are different findings.

What if the fetus is in a bad position and a good measurement cannot be obtained transabdominally?

If the initial transabdominal approach is unsuccessful due to fetal position, the sonographer may ask the patient to walk around, empty their bladder, or wait a short period to encourage the fetus to move. If these maneuvers fail, a transvaginal ultrasound is the appropriate next step, as it is rated ‘May be appropriate’ and can often obtain the necessary view.

Is it necessary to order a transvaginal ultrasound in a patient with a high body mass index (BMI)?

No, it is not necessary to order it as the initial study. The standard workflow is to always begin with a transabdominal ultrasound. While image quality can be more challenging in patients with a high BMI, it is often still adequate. The decision to add a transvaginal scan should be made by the imaging team at the time of the scan if the transabdominal images are found to be suboptimal.

Does this screening process apply to twin pregnancies?

Yes, this routine screening workflow applies to both singleton and twin gestations. For twins, it is critical to determine chorionicity (whether they share a placenta) at this first scan. Nuchal translucency measurements are obtained for each fetus individually and can be incorporated into risk calculations for aneuploidy for each twin.

If a patient has already had cell-free DNA (cfDNA) screening with a low-risk result, is an NT scan still necessary?

This is a complex question with evolving practice standards. While cfDNA is a superior screening test for common aneuploidies, the NT scan provides important information that cfDNA does not. A significantly increased NT can be an early marker for major cardiac defects or other genetic syndromes not covered by cfDNA. Many centers recommend performing both, or at least offering the 11-14 week scan for an early anatomic assessment regardless of cfDNA results.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 29, 2026